{
    "nct_id": "NCT04874480",
    "official_title": "Phase I Study of Tegavivint (BC-2059) in Patients With Relapsed and Refractory Leukemias",
    "inclusion_criteria": "* Patients with a diagnosis of histologically confirmed relapsed or refractory (R/R) acute myeloid leukemia for which no available standard therapies are indicated or anticipated to result in a durable response\n* Age >= 18 years\n* Patients must not have had leukemia therapy for 14 days prior to starting tegavivint (BC-2059). However, patients with rapidly proliferative disease may receive hydroxyurea as needed until 24 hours prior to starting therapy on this protocol and during the first cycle of study\n* Bilirubin =< 2.5 mg/dL\n* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) - or =< 5 x ULN if related to leukemic involvement\n* Creatinine =< 1.5 x ULN\n* Known cardiac ejection fraction of > or = 45% within the past 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status of =< 2\n* A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial\n* Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant women are excluded from this study because the agent used in this study has the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided\n* Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patient with documented hypersensitivity to any of the components of the therapy program\n* Patients with active, uncontrolled central nervous system (CNS) leukemia will not be eligible\n* Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use at least 1 form of barrier birth control (such as condom) prior to study entry and for the duration of study participation\n* Prior treatment with tegavivint",
    "miscellaneous_criteria": ""
}